Company intelligence / Profile preview
ExcelMab
Guangzhou, Guangdong, Chinaexcelmab.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
The company has two bispecific antibody drugs (EX101 and EX103) in Phase 1 clinical trials. EX103, the first CD20×CD3 bispecific antibody developed independently in China, has demonstrated a higher safety profile than similar molecules in preclinical studies. EX101, a new generation HER2×CD3 bispecific antibody, has shown potent anti-tumor effects and excellent safety in preclinical data.
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodiesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on ExcelMab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExcelMab.